Nuvectis Pharma Analyst Ratings
Nuvectis Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/15/2023 | 49.79% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 03/07/2023 | 49.79% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 02/10/2023 | 49.79% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 07/13/2022 | 49.79% | Ladenburg Thalmann | → $21 | Initiates Coverage On | → Buy |
| 05/10/2022 | 49.79% | HC Wainwright & Co. | $14 → $21 | Maintains | Buy |
| 03/02/2022 | -0.14% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023/09/15 | 49.79% | HC Wainwright公司 | →$21 | 重申 | 購買→購買 |
| 03/07/2023 | 49.79% | HC Wainwright公司 | →$21 | 重申 | →購買 |
| 02/10/2023 | 49.79% | HC Wainwright公司 | →$21 | 重申 | →購買 |
| 07/13/2022 | 49.79% | 拉登堡·塔爾曼 | →$21 | 開始承保 | →購買 |
| 2022年05月10日 | 49.79% | HC Wainwright公司 | $14→$21 | 維護 | 買 |
| 03/02/2022 | -0.14% | HC Wainwright公司 | →$14 | 開始承保 | →購買 |
What is the target price for Nuvectis Pharma (NVCT)?
Nuvetis Pharma(NVCT)的目標價是多少？
The latest price target for Nuvectis Pharma (NASDAQ: NVCT) was reported by HC Wainwright & Co. on September 15, 2023. The analyst firm set a price target for $21.00 expecting NVCT to rise to within 12 months (a possible 49.79% upside). 3 analyst firms have reported ratings in the last year.
新維蒂斯製藥公司(納斯達克代碼：NVCT)的最新目標價是由HC Wainwright&Co.於2023年9月15日報道的。這家分析公司將目標價定為21.00美元，預計NVCT將在12個月內上漲至49.79%。3家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Nuvectis Pharma (NVCT)?
紐維蒂斯製藥公司(Nuvetis Pharma)最近的分析師評級是多少？
The latest analyst rating for Nuvectis Pharma (NASDAQ: NVCT) was provided by HC Wainwright & Co., and Nuvectis Pharma reiterated their buy rating.
新維蒂斯製藥公司(納斯達克代碼：NVCT)的最新分析師評級由HC Wainwright&Co.提供，新維蒂斯製藥公司重申其買入評級。
When is the next analyst rating going to be posted or updated for Nuvectis Pharma (NVCT)?
Nuvetis Pharma(NVCT)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvectis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvectis Pharma was filed on September 15, 2023 so you should expect the next rating to be made available sometime around September 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Nuvetis Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Nuvetis Pharma的上一次評級是在2023年9月15日提交的，所以你應該預計下一次評級將在2024年9月15日左右的某個時候公佈。
Is the Analyst Rating Nuvectis Pharma (NVCT) correct?
分析師對Nuvetis Pharma(NVCT)的評級正確嗎？
While ratings are subjective and will change, the latest Nuvectis Pharma (NVCT) rating was a reiterated with a price target of $0.00 to $21.00. The current price Nuvectis Pharma (NVCT) is trading at is $14.02, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Nuvetis Pharma(NVCT)評級被重申，目標價在0.00美元至21.00美元之間。Nuvetis Pharma目前的交易價格為14.02美元，在分析師的預測範圍內。